Regulatory T cells in vitiligo: Implications for pathogenesis and therapeutics

Autoimmunity Reviews

Volumn 14, Issue 1, 2015, Pages 49-56

  Dwivedi, Mitesh ^a,c   Helen Kemp, E ^b   Laddha, Naresh C ^c   Mansuri, Mohmmad Shoab ^c   Weetman, Anthony P ^b   Begum, Rasheedunnisa ^c  

^a UKA TARSADIA UNIVERSITY   (India)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c M S UNIVERSITY OF BARODA   (India)

Author keywords

Autoimmunity; CD8^{+< sup> T cells; Melanocyte; Pigmentation; Regulatory T cells; Vitiligo}

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 5; MONOCLONAL ANTIBODY CD3; POLYSACCHARIDE; PROBIOTIC AGENT; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR;

ACIDITY; ADOPTIVE TRANSFER; ANTIBODY PRODUCTION; ANTIGEN SPECIFICITY; B LYMPHOCYTE; GENETIC SUSCEPTIBILITY; GINSENG; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; LYMPHOCYTIC INFILTRATION; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; TH2 CELL; VITILIGO; ANIMAL; CYTOLOGY; IMMUNOLOGY; MELANOCYTE; PATHOLOGY;

ANIMALS; HUMANS; MELANOCYTES; SELF TOLERANCE; T-LYMPHOCYTES, REGULATORY; VITILIGO;

EID: 84922952145     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.10.002     Document Type: Review

References (110)

1. Taïeb A., Picardo M. Epidemiology, definitions and classification. Vitiligo 2010, 13-24. Springer-Verlag, Berlin. A. Taïeb, M. Picardo (Eds.).
2. Taïeb A., Picardo M. Management overview. Vitiligo 2010, 319-323. Springer-Verlag, Berlin. A. Taïeb, M. Picardo (Eds.).
3. Ongenae K., Beelaert L., van Geel N., Naeyaert J.M. Psychosocial effects of vitiligo. J Eur Acad Dermatol Venereol 2006, 20:1-8.
4. Ongenae K., Dierckxsens L., Brochez L., van Geel N., Naeyaert J.M. Quality of life and stigmatization profile in a cohort of vitiligo patients and effect of the use of camouflage. Dermatology 2005, 210:279-285.
5. Le Poole I., Luiten R. Autoimmune etiology of generalized vitiligo. Curr Dir Autoimmun 2008, 10:227-243.
6. Mosenson J.A., Zloza A., Klarquist J., Barfuss A.J., Guevara-Patino J.A., Poole I.C. HSP70i is a critical component of the immune response leading to vitiligo. Pigment Cell Melanoma Res 2012, 25:88-98.
7. van den Boorn J.G., Konijnenberg D., Dellemijn T.A., van der Veen J.P., Bos J.D., Melief C.J., et al. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol 2009, 129:2220-2232.
8. Spritz R.A. Six decades of vitiligo genetics: genome-wide studies provide insights into autoimmune pathogenesis. J Invest Dermatol 2012, 132:268-273.
9. Wu J., Zhou M., Wan Y., Xu A. CD8+ T cells from vitiligo perilesional margins induce autologous melanocyte apoptosis. Mol Med Rep 2013, 7:237-241.
10. Lili Y., Yi W., Ji Y., Yue S., Weimin S., Ming L. Global activation of CD8+ cytotoxic T lymphocytes correlates with an impairment in regulatory T cells in patients with generalized vitiligo. PLoS One 2012, 7:e37513.
11. Dwivedi M., Laddha N.C., Arora P., Marfatia Y.S., Begum R. Decreased regulatory T-Cells and CD4+/CD8+ ratio correlate with disease onset and progression in patients with generalized vitiligo. Pigment Cell Melanoma Res 2013, 26:586-591.
12. Wankowicz-Kalinska A., van den Wijngaard R.M., Tigges B.J., Westerhof W., Ogg G.S., Cerundolo V., et al. Immunopolarization of CD4+ and CD8+ T cells to type-1-like is associated with melanocyte loss in human vitiligo. Lab Invest 2003, 83:683-695.
13. Ben Ahmed M., Zaraa I., Rekik R., Elbeldi-Ferchiou A., Kourda N., Belhadj Hmida N., et al. Functional defects of peripheral regulatory T lymphocytes in patients with progressive vitiligo. Pigment Cell Melanoma Res 2012, 25:99-109.
14. Levings M., Sangregorio R., Roncarolo M. Human CD25(+)CD4(+) T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 2001, 193:1295-1302.
15. Maloy K., Powrie F. Regulatory T-cells in the control of immune pathology. Nat Immunol 2001, 2:816-822.
16. Zhang P., CÔté A.L., de Vries V.C., Usherwood E.J., Turk M.J. Induction of postsurgical tumor immunity and T-cell memory by a poorly immunogenic tumor. Cancer Res 2007, 1:6468-6476.
17. Eby J.M., Kang H.K., Klarquist J., Chatterjee S., Mosenson J.A., Nishimura M.I., et al. Immune responses in a mouse model of vitiligo with spontaneous epidermal de- and repigmentation. Pigment Cell Melanoma Res 2014, 10.1111/pcmr.12284.
18. Abdallah M., Lotfi R., Othman W., Galal R. Assessment of tissue FoxP3+, CD4+ and CD8+ T-cells in active and stable nonsegmental vitiligo. Int J Dermatol 2014, 53:940-946.
19. Ono S., Tanizaki H., Otsuka A., Endo Y., Koyanagi I., Kataoka T.R., et al. Coexistent skin lesions of vitiligo and psoriasis vulgaris. Immunohistochemical analyses for IL-17A-producing cells and regulatory T cells. Acta Derm Venereol 2014, 94:329-330.
20. Terras S., Gambichler T., Moritz R.K., Altmeyer P., Lambert J. Immunohistochemical analysis of FOXP3+ regulatory T cells in healthy human skin and autoimmune dermatoses. Int J Dermatol 2014, 53:294-299.
21. Zhou L., Li K., Shi Y.L., Hamzavi I., Gao T.W., Henderson M., et al. Systemic analyses of immunophenotypes of peripheral T cells in non-segmental vitiligo: implication of defective natural killer T cells. Pigment Cell Melanoma Res 2012, 25:602-611.
22. Abdallah M., Saad A. Evaluation of circulating CD4+CD25highFoxP3+ T lymphocytes in active non-segmental vitiligo. J Pan-Arab League Dermatol 2009, 20:1.
23. Klarquist J., Denman C.J., Hernandez C., Wainwright D.A., Strickland F.M., Overbeck A., et al. Reduced skin homing by functional Treg in vitiligo. Pigment Cell Melanoma Res 2010, 23:276-286.
24. Elela M.A., Hegazy R.A., Fawzy M.M., Rashed L.A., Rasheed H. Interleukin 17, interleukin 22 and FoxP3 expression in tissue and serum of non-segmental vitiligo: a case-controlled study on eighty-four patients. Eur J Dermatol 2013, 23:350-355.
25. Hegazy R.A., Fawzy M.M., Gawdat H.I., Samir N., Rashed L.A. T helper 17 and Tregs: a novel proposed mechanism for NB-UVB in vitiligo. Exp Dermatol 2014, 23:283-286.
26. Moftah N.H., El-Barbary R.A., Ismail M.A., Ali N.A. Effect of narrow band-ultraviolet B on CD4+ CD25highFoxP3+ T-lymphocytes in the peripheral blood of vitiligo patients. Photodermatol Photoimmunol Photomed 2013, 10.1111/phpp.12104.
27. Richetta A., D'Epiro S., Salvi M., Campoli M., Giancristoforo S., Mattozzi C., et al. Serum levels of functional T-regs in vitiligo: our experience and mini-review of the literature. Eur J Dermatol 2013, 23:154-159.
28. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor FOXP3. Science 2003, 299:1057-1061.
29. Yagi H., Nomura T., Nakamura K., Yamazaki S., Kitawaki T., Hori S., et al. Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T-cells. Int Immunol 2004, 16:1643-1656.
30. Bettelli E., Dastrange M., Oukka M. Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells. Proc Natl Acad Sci U S A 2005, 102:5138-5143.
31. Zheng Y., Rudensky A.Y. FoxP3 in control of the regulatory T cell lineage. Nat Immunol 2007, 8:457-462.
32. Fontenot J.D., Gavin M.A., Rudensky A.Y. FoxP3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003, 4:330-336.
33. Kim J., Lahl K., Hori S., Loddenkemper C., Chaudhry A., de Roos P., et al. Cutting edge: depletion of FoxP3+ cells leads to induction of autoimmunity by specific ablation of regulatory T cells in genetically targeted mice. J Immunol 2009, 183:7631-7634.
34. Bennett C., Christie J., Ramsdell F., Brunkow M., Ferguson P., Whitesell L., et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001, 27:20-21.
35. Wildin R.S., Smyk-Pearson S., Filipovich A.H. Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med Genet 2002, 39:537-545.
36. van der Vliet H.J., Nieuwenhuis E.E. IPEX as a result of mutations in FOXP3. Clin Dev Immunol 2007, 2007:89017.
37. Bassuny W.M., Ihara K., Sasaki Y., Kuromaru R., Kohno H., Matsuura N., et al. A functional polymorphism in the promoter/enhancer region of the FOXP3/Scurfin gene associated with type 1 diabetes. Immunogenetics 2003, 55:149-156.
38. Inoue N., Watanabe M., Morita M., Tomizawa R., Akamizu T., Tatsumi K., et al. Association of functional polymorphisms related to the transcriptional level of FOXP3 with prognosis of autoimmune thyroid diseases. Clin Exp Immunol 2010, 162:402-406.
39. Song P., Wang X.W., Li H.X., Li K., Liu L., Wei C., et al. Association between FOXP3 polymorphisms and vitiligo in a Han Chinese population. Br J Dermatol 2013, 169:571-578.
40. Jahan P., Cheruvu R., Tippisetty S., Komaravalli P.L., Valluri V., Ishaq M. Association of FOXP3 (rs3761548) promoter polymorphism with nondermatomal vitiligo: a study from India. J Am Acad Dermatol 2013, 69:262-266.
41. Birlea S.A., Jin Y., Bennett D.C., Herbstman D.M., Wallace M.R., McCormack W.T., et al. Comprehensive association analysis of candidate genes for generalized vitiligo supports XBP1, FOXP3, and TSLP. J Invest Dermatol 2011, 131:371-381.
42. Gribben J.G., Freeman G.J., Boussiotis V.A., Rennert P., Jellis C.L., Greenfield E., et al. CTLA4 mediates antigen-specific apoptosis of human T cells. Proc Natl Acad Sci U S A 1995, 92:811-815.
43. Romo-Tena J., Gómez-Martín D., Alcocer-Varela J. CTLA-4 and autoimmunity: new insights into the dual regulator of tolerance. Autoimmun Rev 2013, 12:1171-1176.
44. Waterhouse P., Penninger J.M., Timms E., Wakeham A., Shahinian A., Lee K.P., et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995, 270:985-988.
45. Chen Z., Stockton J., Mathis D., Benoist C. Modeling CTLA4-linked autoimmunity with RNA interference in mice. Proc Natl Acad Sci U S A 2006, 103:16400-16405.
46. Dwivedi M., Laddha N.C., Imran M., Shah B.J., Begum R. Cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) in isolated vitiligo: a genotype-phenotype correlation. Pigment Cell Melanoma Res 2011, 24:737-740.
47. Gerold K.D., Zheng P., Rainbow D.B., Zernecke A., Wicker L.S., Kissler S. The soluble CTLA-4 splice variant protects from type 1 diabetes and potentiates regulatory T-cell function. Diabetes 2011, 60:1955-1963.
48. Saverino D., Brizzolara R., Simone R., Chiappori A., Milintenda-Floriani F., Pesce G., et al. Soluble CTLA-4 in autoimmune thyroid diseases: relationship with clinical status and possible role in the immune response dysregulation. Clin Immunol 2007, 123:190-198.
49. Bala K.K., Moudgil K.D. Induction and maintenance of self tolerance: the role of CD4+CD25+ regulatory T cells. Arch Immunol Ther Exp (Warsz) 2006, 54:307-321.
50. Joetham A., Takeda K., Taube C., Miyahara N., Matsubara S., Koya T., et al. Naturally occurring lung CD4(+)CD25(+) T cell regulation of airway allergic responses depends on IL-10 induction of TGF-b. J Immunol 2007, 178:1433-1442.
51. Zhu J., Paul W.W. CD4 T cells: fates, functions, and faults. Blood 2008, 112:1557-1569.
52. Zheng S.G., Gray J.D., Ohtsuka K., Yamagiwa S., Horwitz D.A. Generation ex vivo of TGF-beta-producing regulatory T cells from CD4+CD25- precursors. J Immunol 2002, 169:4183-4189.
53. Fu S., Zhang N., Yopp A.C., Chen D., Mao M., Chen D., et al. TGF-beta induces FoxP3+ T-regulatory cells from CD4+CD25- precursors. Am J Transplant 2004, 4:1614-1627.
54. Fantini M.C., Becker C., Monteleone G., Pallone F., Galle P.R., Neurath M.F. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through FoxP3 induction and down-regulation of Smad7. J Immunol 2004, 172:5149-5153.
55. Zheng S.G., Wang J.H., Gray J.D., Soucier H., Horwitz D.A. Natural and induced CD4+CD25+ cells educate CD4+CD25- cells to develop suppressive activity: the role of IL-2, TGF-beta, and IL-10. J Immunol 2004, 172:5213-5221.
56. Liang S., Alard P., Zhao Y., Parnell S., Clark S.L., Kosiewicz M.M. Conversion of CD4+ CD25- cells into CD4+CD25+ regulatory T cells in vivo requires B7 costimulation, but not the thymus. J Exp Med 2005, 201:127-137.
57. Chen W., Konkel J.E. TGF-beta and 'adaptive' FoxP3+ regulatory T cells. J Mol Cell Biol 2010, 2:30-36.
58. Basak P.Y., Adiloglu A.K., Ceyhan A.M., Tas T., Akkaya V.B. The role of helper and regulatory T cells in the pathogenesis of vitiligo. J Am Acad Dermatol 2009, 60:256-260.
59. Khan R., Gupta S., Sharma A. Circulatory levels of T-cell cytokines interleukin (IL)-2, IL-4, IL-17, and transforming growth factor-β in patients with vitiligo. J Am Acad Dermatol 2012, 66:510-511.
60. Moretti S., Spallanzani A., Amato L., Hautmann G., Gallerani I., Fabiani M., et al. New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res 2002, 15:87-92.
61. Tembhre M.K., Sharma V.K., Sharma A., Chattopadhyay P., Gupta S. T helper and regulatory T cell cytokine profile in active, stable and narrow band ultraviolet B treated generalized vitiligo. Clin Chim Acta 2013, 424:27-32.
62. Tu C.X., Jin W.W., Lin M., Wang Z.H., Man M.Q. Levels of TGF-β(1) in serum and culture supernatants of CD4(+)CD25(+) T cells from patients with non-segmental vitiligo. Arch Dermatol Res 2011, 303:685-689.
63. Yun J.Y., Uhm Y.K., Kim H.J., Lim S.H., Chung J.H., Shin M.K., et al. Transforming growth factor beta receptor II (TGFBR2) polymorphisms and the association with nonsegmental vitiligo in the Korean population. Int J Immunogenet 2010, 37:289-291.
64. O'Garra A., Vieira P.L., Vieira P., Goldfeld A.E. IL-10-producing and naturally occurring CD4+ Tregs: limiting collateral damage. J Clin Invest 2004, 114:1372-1378.
65. Dejaco C., Duftner C., Grubeck-Loebenstein B., Schermer M. Imbalance of regulatory T cells in human autoimmune diseases. Immunol 2006, 117:289-300.
66. Taher Z.A., Lauzon G., Maguiness S., Dytoc M.T. Analysis of interleukin-10 levels in lesions of vitiligo following treatment with topical tacrolimus. Br J Dermatol 2009, 161:654-659.
67. Abanmi A., Al Harthi F., Zouman A., Kudwah A., Jamal M.A., Arfin M., et al. Association of interleukin-10 gene promoter polymorphisms in Saudi patients with vitiligo. Dis Markers 2008, 24:51-57.
68. Shi F., Erf G.F. IFN-γ, IL-21, and IL-10 co-expression in evolving autoimmune vitiligo lesions of Smyth line chickens. J Invest Dermatol 2012, 132:642-649.
69. Pommier A., Audemard A., Durand A., Lengagne R., Delpoux A., Martin B., et al. Inflammatory monocytes are potent antitumor effectors controlled by regulatory CD4+ T cells. Proc Natl Acad Sci U S A 2013, 110:13085-13090.
70. Chen L.C., Delgado J.C., Jensen P.E., Chen X. Direct expansion of human allospecific FoxP3+CD4+ regulatory T cells with allogeneic B cells for therapeutic application. J Immunol 2009, 183:4094-4102.
71. Brusko T.M., Koya R.C., Zhu S., Lee M.R., Putnam A.L., McClymont S.A., et al. Human antigen-specific regulatory T cells generated by T cell receptor gene transfer. PLoS One 2010, 5:e11726.
72. Lan Q., Fan H., Quesniaux V., Ryffel B., Liu Z., Zheng S.G. Induced FoxP3(+) regulatory T cells: a potential new weapon to treat autoimmune and inflammatory diseases?. J Mol Cell Biol 2012, 4:22-28.
73. Zheng S.G., Wang J.H., Koss M.N., Quismorio F., Gray J.D., Horwitz D.A. CD4+ and CD8+ regulatory T cells generated ex vivo with IL-2 and TGF-beta suppress a stimulatory graft-versus-host disease with a lupus-like syndrome. J Immunol 2004, 172:1531-1539.
74. Selvaraj R.K., Geiger T.L. Mitigation of experimental allergic encephalomyelitis by TGF-beta induced FoxP3+ regulatory T lymphocytes through the induction of anergy and infectious tolerance. J Immunol 2008, 180:2830-2838.
75. Nguyen T.L., Sullivan N.L., Ebel M., Teague R.M., DiPaolo R.J. Antigen-specific TGF-beta-induced regulatory T cells secrete chemokines, regulate T cell trafficking, and suppress ongoing autoimmunity. J Immunol 2011, 187:1745-1753.
76. DiPaolo R.J., Brinster C., Davidson T.S., Andersson J., Glass D., Shevach E.M. Autoantigen-specific TGFbeta-induced FoxP3+ regulatory T cells prevent autoimmunity by inhibiting dendritic cells from activating autoreactive T cells. J Immunol 2007, 179:4685-4693.
77. Weber S.E., Harbertson J., Godebu E., Mros G.A., Padrick R.C., Carson B.D., et al. Adaptive islet-specific regulatory CD4 T cells control autoimmune diabetes and mediate the disappearance of pathogenic Th1 cells in vivo. J Immunol 2006, 176:4730-4739.
78. Fantini M.C., Becker C., Tubbe I., Nikolaev A., Lehr H.A., Galle P., et al. Transforming growth factor beta induced FoxP3+ regulatory T cells suppress Th1-mediated experimental colitis. Gut 2006, 55:671-680.
79. Huter E.N., Stummvoll G.H., DiPaolo R.J., Glass D.D., Shevach E.M. Cutting edge: antigen specific TGF beta-induced regulatory T cells suppress Th17-mediated autoimmune disease. J Immunol 2008, 181:8209-8213.
80. Chen W., Jin W., Hardegen N., Lei K.J., Li L., Marinos N., et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor FoxP3. J Exp Med 2003, 198:1875-1886.
81. Chatterjee S., Eby J.M., Al-Khami A.A., Soloshchenko M., Kang H.K., Kaur N., et al. A quantitative increase in regulatory T cells controls development of vitiligo. J Invest Dermatol 2014, 134:1285-1294.
82. Mosenson J.A., Eby J.M., Hernandez C., Le Poole I.C. A central role for inducible heat-shock protein 70 in autoimmune vitiligo. Exp Dermatol 2013, 22:566-569.
83. Mosenson J.A., Zloza A., Nieland J.D., Garrett-Mayer E., Eby J.M., Huelsmann E.J., et al. Mutant HSP70 reverses autoimmune depigmentation in vitiligo. Sci Transl Med 2013, 5:174ra28.
84. Van Herwijnen M.J., Van Der Zee R., Van Eden W., Broere F. Heat shock proteins can be targets of regulatory T cells for therapeutic intervention in rheumatoid arthritis. Int J Hyperthermia 2013, 29:448-454.
85. Bluestone J.A., Tang Q. Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T cells. Proc Natl Acad Sci U S A 2004, 101:14622-14626.
86. Wright G.P., Notley C.A., Xue S.A., Bendle G.M., Holler A., Schumacher T.N., et al. Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis. Proc Natl Acad Sci U S A 2009, 106:19078-19083.
87. Konieczna P., Akdis C.A., Quigley E.M., Shanahan F., O'Mahony L. Portrait of an immunoregulatory Bifidobacterium. Gut Microbes 2012, 3:261-266.
88. Fuller R. Probiotics in man and animals. J Appl Bacteriol 1989, 66:365-378.
89. Konieczna P., Groeger D., Ziegler M., Frei R., Ferstl R., Shanahan F., et al. Bifidobacterium infantis 35,624 administration induces FoxP3 T regulatory cells in human peripheral blood: potential role for myeloid and plasmacytoid dendritic cells. Gut 2012, 61:354-366.
90. O'Mahony C., Scully P., O'Mahony D., Murphy S., O'Brien F., Lyons A., et al. Commensal-induced regulatory T cells mediate protection against pathogen-stimulated NFkappaB activation. PLoS Pathog 2008, 4:e1000112.
91. O'Mahony L., McCarthy J., Kelly P., Hurley G., Luo F., Chen K., et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005, 128:541-551.
92. Whorwell P.J., Altringer L., Morel J., Bond Y., Charbonneau D., O'Mahony L., et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35,624 in women with irritable bowel syndrome. Am J Gastroenterol 2006, 101:1581-1590.
93. Feleszko W., Jaworska J., Rha R.D., Steinhausen S., Avagyan A., Jaudszus A., et al. Probiotic-induced suppression of allergic sensitization and airway inflammation is associated with an increase of T regulatory-dependent mechanisms in a murine model of asthma. Clin Exp Allergy 2007, 37:498-505.
94. Kwon H.K., Lee C.G., So J.S., Chae C.S., Hwang J.S., Sahoo A., et al. Generation of regulatory dendritic cells and CD4+FoxP3+ T cells by probiotics administration suppresses immune disorders. Proc Natl Acad Sci U S A 2010, 107:2159-2164.
95. Kim H.J., Kim Y.J., Lee S.H., Yu J., Jeong S.K., Hong S.J. Effects of Lactobacillus rhamnosus on allergic march model by suppressing Th2, Th17, and TSLP responses via CD4(+)CD25(+)FoxP3(+) Tregs. Clin Immunol 2014, 153:178-186.
96. Lavasani S., Dzhambazov B., Nouri M., Fåk F., Buske S., Molin G., et al. A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells. PLoS One 2010, 5:e9009.
97. Hwang I., Ahn G., Park E., Ha D., Song J.Y., Jee Y. An acidic polysaccharide of Panax ginseng ameliorates experimental autoimmune encephalomyelitis and induces regulatory T cells. Immunol Lett 2011, 138:169-178.
98. Ahmad S.F., Zoheir K.M., Bakheet S.A., Ashour A.E., Attia S.M. Poly(ADP-ribose) polymerase-1 inhibitor modulates T regulatory and IL-17 cells in the prevention of adjuvant induced arthritis in mice model. Cytokine 2014, 68:76-85.
99. Tran G.T., Hodgkinson S.J., Carter N.M., Verma N.D., Plain K.M., Boyd R., et al. IL-5 promotes induction of antigen-specific CD4+CD25+ T regulatory cells that suppress autoimmunity. Blood 2012, 119:4441-4450.
100. Rouse M., Nagarkatti M., Nagarkatti P.S. The role of IL-2 in the activation and expansion of regulatory T-cells and the development of experimental autoimmune encephalomyelitis. Immunobiology 2013, 218:674-682.
101. Long S.A., Cerosaletti K., Bollyky P.L., Tatum M., Shilling H., Zhang S., et al. Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects. Diabetes 2010, 59:407-415.
102. Aoki C.A., Roifman C.M., Lian Z.X., Bowlus C.L., Norman G.L., Shoenfeld Y., et al. IL-2 receptor alpha deficiency and features of primary biliary cirrhosis. J Autoimmun 2006, 27:50-53.
103. Singh R.P., Hahn B.H., La Cava A. Tuning immune suppression in systemic autoimmunity with self-derived peptides. Inflamm Allergy Drug Targets 2008, 7:253-259.
104. Pozo D., Anderson P., Gonzalez-Rey E. Induction of alloantigen-specific human T regulatory cells by vasoactive intestinal peptide. J Immunol 2009, 183:4346-4359.
105. Bisikirska B., Colgan J., Luban J., Bluestone J.A., Herold K.C. TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest 2005, 115:2904-2913.
106. Sheng J.R., Li L.C., Ganesh B.B., Prabhakar B.S., Meriggioli M.N. Regulatory T cells induced by GM-CSF suppress ongoing experimental myasthenia gravis. Clin Immunol 2008, 128:172-180.
107. Walters S.N., Webster K.E., Daley S., Grey S.T. A role for intrathymic B cells in the generation of natural regulatory T cells. J Immunol 2014, 193:170-176.
108. Ju J.H., Heo Y.J., Cho M.L., Jhun J.Y., Park J.S., Lee S.Y., et al. Modulation of STAT-3 in rheumatoid synovial T cells suppresses Th17 differentiation and increases the proportion of Treg cells. Arthritis Rheum 2012, 64:3543-3552.
109. Noack M., Miosse P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev 2014, 13:668-677.
110. Askenasy N. Enhanced killing activity of regulatory T cells ameliorates inflammation and autoimmunity. Autoimmun Rev 2013, 12:972-975.